ROSN:RUSRosneft Analysis
Data as of 2026-05-25 - not real-time
$0.02
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Rosinbomb (ROSN) is trading at $0.0198, sitting below its 20‑day (≈$0.0213) and 50‑day (≈$0.0220) simple moving averages but above the 200‑day SMA (≈$0.0170), indicating a short‑term pull‑back within a longer‑term uptrend. The 14‑day RSI of 44.6 suggests the stock is neither overbought nor oversold, while the MACD histogram remains negative, signaling bearish momentum. Volume is increasing and the 30‑day volatility is extremely high at >117%, reflecting a very active but unstable price environment. Despite a low beta of 0.36, the market’s “Extreme Greed” sentiment (fear‑greed index 91.8) may be inflating demand for this speculative micro‑cap. Fundamentally, ROSN reports zero revenue, negative trailing EPS, and no cash or debt balances, with a market cap of roughly $9 million and a historic max drawdown of 50%.
Given the lack of earnings, thin liquidity, and high price swings, the stock is best viewed as a high‑risk speculative play. The technical picture is neutral to slightly bearish, and without a clear catalyst or revenue trajectory, investors should approach ROSN cautiously, treating any exposure as a short‑term tactical position rather than a core holding.
Given the lack of earnings, thin liquidity, and high price swings, the stock is best viewed as a high‑risk speculative play. The technical picture is neutral to slightly bearish, and without a clear catalyst or revenue trajectory, investors should approach ROSN cautiously, treating any exposure as a short‑term tactical position rather than a core holding.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD histogram
- Neutral RSI around 45
- Increasing volume amid high volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- No revenue or earnings generation
- Extreme market greed environment
- Low beta but very high price volatility
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Fundamental data absent (zero revenue, negative EPS)
- Small market cap and thin liquidity
- Potential upside only if the company launches revenue‑producing products
Key Metrics & Analysis
Financial Health
Industry P/E29.7
Technical Analysis
TrendNeutral
RSI44.6
Support$0.01
Resistance$0.02
MA 20$0.02
MA 50$0.02
MA 200$0.02
MACDBearish
VolumeIncreasing
Fear & Greed Index91.8
Valuation
GradeFair
TypeValue
Risk Assessment
Beta0.36
Volatility117.83%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.